category,datetime,headline,id,image,related,source,summary,url
company,1769032800,New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer,138199642,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,GILD,Yahoo,"FOSTER CITY, Calif., January 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65;",https://finnhub.io/api/news?id=6ca9e347862f77027968a3ec728b9b1bd622e9d5125a15e92321486b12d5b6db
company,1769013360,Gilead Sciences Inc. stock outperforms competitors on strong trading day,138209414,,GILD,MarketWatch,Gilead Sciences Inc. stock outperforms competitors on strong trading day,https://finnhub.io/api/news?id=c1c88429c6a789ce59f221866d9b6f071e118bc92fa39f5ad453ae0d5e9ae845
company,1769004563,Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness,138196102,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,GILD,Yahoo,"Why Gilead Sciences (GILD) Is on Investors’ Radar Today Gilead Sciences (GILD) is drawing investor attention after recent trading left the stock with a 1-day return of about a 1% decline, alongside modest moves over the week and month. See our latest analysis for Gilead Sciences. That small 1 day share price decline sits against a steadier backdrop, with a 7 day share price return of 1.95% and a year to date share price return of 2.09%, while the 1 year total shareholder return of 37.27%...",https://finnhub.io/api/news?id=3e618c032799101d91ade82a6b4fb8c9d4edf7f09c67a99a0235d988c1f09b77
